biospace med
Clinical study demonstrates EOS reduces patient's radiation exposure by up to 89% compared to standard CR x-rays while substantially improving image quality
Published in Clinical Trials Week, April 26th, 2010
biospace med (www.biospacemed.com) announced that a 50-patient clinical study published in the current issue of the peer-reviewed medical journal Spine demonstrates that the Company's ultra-low-dose 2D/3D imaging system, EOS, shows "significantly better" image quality compared to a CR (Computed Radiography) x-ray system while "substantially reducing (a) patient's (radiation) dose exposure" by up to 9 times (89%) compared to CR imaging. EOS is FDA-cleared and CE-marked.
The study1 was conducted under the supervision of principal investigator Stefan Parent, M.D., Ph.D., Centre Hospitalier Universitaire Sainte-Justine, Montreal. It included 50 patients (39 girls, 11 boys;...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2010-04-26)
More Articles from Clinical Trials Week
- Buck Institute for Age Research
Antidepressants as treatment immediately following a stroke? - World Journal of Gastroenterology
Diabetic factors associated with gastrointestinal symptoms - World Journal of Gastroenterology
Perioperative chemoradiotherapy in esophageal squamous cell carcinoma - Aeolus Pharmaceuticals, Inc.
Aeolus Pharmaceuticals Announces the Initiation of a Second Study of AEOL 10150 as a Medical Countermeasure for GI Acute Radiation Syndrome Funded by the National Institutes of Health's National Institute for Allergy and Infectious Diseases - American Academy of Dermatology
New Study Evaluates Effectiveness of Vitamins for the Treatment of Sun-Damaged Skin - Erectile Dysfunction
Cedars-Sinai Heart Institute Researcher Awarded Grant to Study Whether Erectile Dysfunction Drugs Can Improve Muscle Blood Flow in Muscular Dystrophy Patients - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
